Onconetix, Inc.
ONCOOnconetix is a commercial-stage biotechnology company specializing in innovative diagnostic and therapeutic solutions for men's health and oncology.
Table of contents
Earnings
Next report
Aug 17, 2026 (in a month)Competitors
By market cap
Profile
Onconetix is a commercial-stage biotechnology company specializing in innovative diagnostic and therapeutic solutions for men's health and oncology. The company's primary focus is the commercialization of Proclarix, a non-invasive, protein-based blood test designed to improve the accuracy of prostate cancer screening and reduce unnecessary biopsies. By integrating proprietary biomarkers with clinical decision support algorithms, the company aims to address overdiagnosis and overtreatment in the prostate cancer diagnostic pathway.
Onconetix is a specialized player in the prostate cancer diagnostic niche, leveraging a CE-marked product under the new IVDR regulations to compete against established laboratory-developed tests.
Questions, answered.
- What is Onconetix, Inc.'s market cap?
- Onconetix, Inc. (ONCO) has a market capitalization of $3.6M and trades on NASDAQ.
- Who are Onconetix, Inc.'s competitors?
- Onconetix, Inc.'s key competitors include OPKO Health, Inc., Abbott Laboratories, Beckman Coulter, Inc., and others. These companies compete in similar markets and product categories.
- Who does Onconetix, Inc. partner with?
- Onconetix, Inc.'s notable partners include LabCorp, Immunovia AB, New Horizon Health Limited, and others.
- What subsidiaries does Onconetix, Inc. have?
- Onconetix, Inc.'s subsidiaries include Proteomedix AG.
- Where is Onconetix, Inc. headquartered?
- Onconetix, Inc. is headquartered in United States of America and employs approximately 12 people. It has been publicly traded since 2022.